Log in
Since 2009 the read heads of all hard disks have used a technology based on magnesium oxide (MgO). The development of this technology can be partly attributed to a 2001 publication [3.1] co-authored by Dr Andrey Umerski of The Open University, which concluded that a system based on MgO would lead to a huge increase in magnetoresistance, a physical property that determines the efficiency of hard disk read heads.
In 2004 these theoretical predictions were confirmed experimentally; by 2008 the new type of read head based on MgO was manufactured commercially, leading to significant increases in storage capacity, from GBs to TBs.
We demonstrate a strong influence on the design of the read head used in the present state-of-the-art hard-disk drive (HDD) first produced commercially in 2008. This much improved read head, enabling disk storage density to increase by a factor of 5 to around 1 Tbit/in2, relies crucially on a magnetic tunnel junction with a MgO barrier whose huge tunneling magnetoresistance was predicted theoretically in a 2001 paper co-authored by Dr A. Umerski [1], the RA on one of our EPSRC-funded research grants. This prediction relied on techniques developed by us over many years, specifically in refs [2] and [3]. Such magnetic tunnel junctions are used in all computer HDDs manufactured today with predicted sales in 2012 amounting to more than $28 billion [section 5, source A].
Research in the Microelectronics Group of the Cavendish Laboratory in the area of single-electron nanoelectronics, quantum computing and spintronics has been exploited by Hitachi, one of world's leading microelectronics companies. Research breakthroughs made in the Cavendish have defined Hitachi's R&D directions in quantum computing and spintronics, led to several Hitachi product developments and influenced senior Hitachi strategic decision makers regarding the future of computing.
A device developed for spintronics research at the University of Oxford has been adapted as the basis for robust, high-performance position or composition sensors to detect many different materials including metals, plastics, ceramics and fluids. These sensors are capable of making contactless measurements in very hostile environments. A spin-out company was formed in 2004 to exploit and apply this technology to a wide range of technical and engineering problems and has achieved over £2.5m revenue. These sensors form the key elements of products that have been successfully deployed in automotive and other transport applications. Benefits to end users include ease of use, speed and the cost savings.
Our research on the physiological effects of the electromagnetic fields generated in magnetic resonance imaging (MRI) has been used by: (i) the International Commission on Non-Ionizing Radiation Protection (ICNIRP) and the UK Health Protection Agency (HPA) in establishing advisory limits and action values in their published regulatory guidelines; (ii) the EU Commission as part of the evidential basis in their decision to derogate MRI from the scope of the Physical Agents Directive 2004/40/EC. These decisions have enabled the continued operation of MR scanners across Europe, safeguarding the access to MRI for 500 million people. The economic benefits arising from the manufacture of MRI equipment were also secured. Our work has thus resulted in impact on public policy, the economy and healthcare.
Groundbreaking UCL research and development of magnetic nanoparticles for biomedical applications led to the introduction in 2012 of the world's first licensed nanoparticulate injectable medical device, the Sienna+ tracer, and its associated detection system, the SentiMag. A UCL spinout company, Endomagnetics Ltd., has introduced this new technology to better diagnose and treat cancer without the need for invasive surgery. The system uses magnetic materials, rather than radioisotopes, to locate the sentinel lymph nodes that are the key indicators of the spread of cancer away from the primary tumour site. As well as improving patient outcomes, the system considerably improves hospital workflow and efficiency since, unlike radioisotopes, the injectable magnetic tracer (Sienna+) is readily available and requires no special handling